{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:12:15Z","timestamp":1787800335978,"version":"build-2784847793"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["ZIA-DA000633"],"award-info":[{"award-number":["ZIA-DA000633"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["ZIA-DA000633"],"award-info":[{"award-number":["ZIA-DA000633"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["ZIA-DA000633"],"award-info":[{"award-number":["ZIA-DA000633"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["ZIA-DD000633"],"award-info":[{"award-number":["ZIA-DD000633"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Co-administration of cannabinoids and opioids has been shown to enhance analgesic effects. However, the underlying mechanisms remain unclear. One hypothesis suggests that cannabinoid CB1 receptors (CB1R) and mu-opioid receptors (MOR) interact at the cell membrane or intracellular signaling level. This study aimed to test this hypothesis by examining CB1R-MOR colocalization and assessing whether the deletion of one receptor affects the other\u2019s response to its ligand. Results from RNAscope in situ hybridization revealed that CB1R and MOR mRNAs exhibit distinct regional distributions in the mouse brain. Colocalization of CB1R and MOR was primarily observed in the paraventricular nucleus of the thalamus (PVT), where ~50% of vesicular glutamate transporter 2 (Vglut2)-positive glutamatergic neurons displayed CB1R-MOR co-expression. In contrast, only a small subset (5%\u201325%) of Vglut2-positive neurons in pain-related regions, such as the periaqueductal gray (PAG) and the dorsal horn of the spinal cord, or vesicular GABA transporter (Vgat)-positive GABA neurons in reward-related regions, such as the nucleus accumbens, ventral tegmental area, and substantia nigra, exhibited such colocalization. Unexpectedly, the selective deletion of MOR from Vglut2-positive glutamatergic neurons or Vgat-positive GABAergic neurons did not alter the effects of \u0394\n                    <jats:sup>9<\/jats:sup>\n                    -tetrahydrocannabinol (\u0394\n                    <jats:sup>9<\/jats:sup>\n                    -THC), including analgesia, hypothermia, catalepsy, rotarod locomotor impairment, or conditioned place aversion. Similarly, CB1R deletion from GABAergic neurons did not affect oxycodone-induced analgesia, hypothermia, or conditioned place preference. These findings do not support the hypothesis of a direct CB1R\u2013MOR interaction. Instead, the enhanced analgesic effects of cannabinoids and opioids may result from the activation of CB1R and MOR in distinct neuronal populations or circuits.\n                  <\/jats:p>","DOI":"10.1038\/s41386-025-02245-6","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:48:39Z","timestamp":1758815319000},"page":"506-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cannabinoid CB1 receptor and mu-opioid receptor interaction: new insights from conditional knockout mice"],"prefix":"10.1038","volume":"51","author":[{"given":"Hannah","family":"Alton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Linz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Hua","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5897-4156","authenticated-orcid":false,"given":"Omar","family":"Soler-Cedeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia","family":"Maras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6482-8104","authenticated-orcid":false,"given":"Zheng-Xiong","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"2245_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1274719","volume":"11","author":"YK Lee","year":"2023","unstructured":"Lee YK, Gold MS, Blum K, Thanos PK, Hanna C, Fuehrlein BS. Opioid use disorder: current trends and potential treatments. Front Public Health. 2023;11:1274719.","journal-title":"Front Public Health"},{"key":"2245_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1055\/s-0044-1787571","volume":"44","author":"DC Fipps","year":"2024","unstructured":"Fipps DC, Oesterle TS, Kolla BP. Opioid maintenance therapy: a review of methadone, buprenorphine, and naltrexone treatments for opioid use disorder. Semin Neurol. 2024;44:441\u201351.","journal-title":"Semin Neurol"},{"key":"2245_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/phar.2115","volume":"38","author":"EA Romero-Sandoval","year":"2018","unstructured":"Romero-Sandoval EA, Fincham JE, Kolano AL, Sharpe BN, Alvarado-Vazquez PA. Cannabis for chronic pain: challenges and considerations. Pharmacotherapy. 2018;38:651\u201362.","journal-title":"Pharmacotherapy"},{"key":"2245_CR4","doi-asserted-by":"publisher","first-page":"462","DOI":"10.2174\/138945010790980303","volume":"11","author":"J Desroches","year":"2010","unstructured":"Desroches J, Beaulieu P. Opioids and cannabinoids interactions: involvement in pain management. Curr Drug Targets. 2010;11:462\u201373.","journal-title":"Curr Drug Targets"},{"key":"2245_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.coph.2009.09.009","volume":"10","author":"I Bushlin","year":"2010","unstructured":"Bushlin I, Rozenfeld R, Devi LA. Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol. 2010;10:80\u20136.","journal-title":"Curr Opin Pharmacol"},{"key":"2245_CR6","first-page":"6","volume":"6","author":"K Befort","year":"2015","unstructured":"Befort K. Interactions of the opioid and cannabinoid systems in reward: insights from knockout studies. Front Pharmacol. 2015;6:6.","journal-title":"Front Pharmacol"},{"key":"2245_CR7","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/npp.2017.51","volume":"42","author":"S Nielsen","year":"2017","unstructured":"Nielsen S, Sabioni P, Trigo JM, Ware MA, Betz-Stablein BD, Murnion B, et al. Opioid-sparing effect of cannabinoids: a systematic review and meta-analysis. Neuropsychopharmacology. 2017;42:1752\u201365.","journal-title":"Neuropsychopharmacology"},{"key":"2245_CR8","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1124\/jpet.102.046870","volume":"305","author":"DL Cichewicz","year":"2003","unstructured":"Cichewicz DL, Welch SP. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther. 2003;305:812\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"2245_CR9","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.neuropharm.2008.07.038","volume":"55","author":"AR Wilson","year":"2008","unstructured":"Wilson AR, Maher L, Morgan MM. Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception. Neuropharmacology. 2008;55:1219\u201325.","journal-title":"Neuropharmacology"},{"key":"2245_CR10","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2174\/1389557520666200313120835","volume":"20","author":"E Ozdemir","year":"2020","unstructured":"Ozdemir E. The role of the cannabinoid system in opioid analgesia and tolerance. Mini Rev Med Chem. 2020;20:875\u201385.","journal-title":"Mini Rev Med Chem"},{"key":"2245_CR11","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1126\/science.276.5321.2048","volume":"276","author":"G Tanda","year":"1997","unstructured":"Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science. 1997;276:2048\u201350.","journal-title":"Science"},{"key":"2245_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0165-6147(99)01339-5","volume":"20","author":"J Manzanares","year":"1999","unstructured":"Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci. 1999;20:287\u201394.","journal-title":"Trends Pharmacol Sci"},{"key":"2245_CR13","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/bjp.2008.175","volume":"154","author":"D da Fonseca Pacheco","year":"2008","unstructured":"da Fonseca Pacheco D, Klein A, de Castro Perez A, da Fonseca Pacheco CM, de Francischi JN, Duarte ID. The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors. Br J Pharmacol. 2008;154:1143\u20139.","journal-title":"Br J Pharmacol"},{"key":"2245_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1476-5381.2009.00310.x","volume":"158","author":"F Pacheco Dda","year":"2009","unstructured":"Pacheco Dda F, Klein A, Perez AC, Pacheco CM, de Francischi JN, Reis GM, et al. Central antinociception induced by mu-opioid receptor agonist morphine, but not delta- or kappa-, is mediated by cannabinoid CB1 receptor. Br J Pharmacol. 2009;158:225\u201331.","journal-title":"Br J Pharmacol"},{"key":"2245_CR15","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1046\/j.1460-9568.2000.00287.x","volume":"12","author":"M Martin","year":"2000","unstructured":"Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci. 2000;12:4038\u201346.","journal-title":"Eur J Neurosci"},{"key":"2245_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0166-4328(00)00311-9","volume":"118","author":"G Cossu","year":"2001","unstructured":"Cossu G, Ledent C, Fattore L, Imperato A, Bohme GA, Parmentier M, et al. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res. 2001;118:61\u20135.","journal-title":"Behav Brain Res"},{"key":"2245_CR17","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0022-3565(24)29469-6","volume":"298","author":"AH Lichtman","year":"2001","unstructured":"Lichtman AH, Sheikh SM, Loh HH, Martin BR. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther. 2001;298:1007\u201314.","journal-title":"J Pharmacol Exp Ther"},{"key":"2245_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1126\/science.283.5400.401","volume":"283","author":"C Ledent","year":"1999","unstructured":"Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 1999;283:401\u20134.","journal-title":"Science"},{"key":"2245_CR19","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1523\/JNEUROSCI.22-03-01146.2002","volume":"22","author":"S Ghozland","year":"2002","unstructured":"Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci. 2002;22:1146\u201354.","journal-title":"J Neurosci"},{"key":"2245_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0006-8993(02)02890-1","volume":"945","author":"OV Rice","year":"2002","unstructured":"Rice OV, Gordon N, Gifford AN. Conditioned place preference to morphine in cannabinoid CB1 receptor knockout mice. Brain Res. 2002;945:135\u20138.","journal-title":"Brain Res"},{"key":"2245_CR21","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2174\/138945010790980312","volume":"11","author":"JA Lopez-Moreno","year":"2010","unstructured":"Lopez-Moreno JA, Lopez-Jimenez A, Gorriti MA, de Fonseca FR. Functional interactions between endogenous cannabinoid and opioid systems: focus on alcohol, genetics and drug-addicted behaviors. Curr Drug Targets. 2010;11:406\u201328.","journal-title":"Curr Drug Targets"},{"key":"2245_CR22","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.pbb.2005.01.021","volume":"81","author":"D Vigano","year":"2005","unstructured":"Vigano D, Rubino T, Parolaro D. Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav. 2005;81:360\u20138.","journal-title":"Pharmacol Biochem Behav"},{"key":"2245_CR23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.neuroscience.2013.04.034","volume":"248","author":"JL Scavone","year":"2013","unstructured":"Scavone JL, Sterling RC, Van Bockstaele EJ. Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience. 2013;248:637\u201354.","journal-title":"Neuroscience"},{"key":"2245_CR24","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/jnr.24770","volume":"100","author":"A Mohammadkhani","year":"2022","unstructured":"Mohammadkhani A, Borgland SL. Cellular and behavioral basis of cannabinioid and opioid interactions: Implications for opioid dependence and withdrawal. J Neurosci Res. 2022;100:278\u201396.","journal-title":"J Neurosci Res"},{"key":"2245_CR25","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1254\/jphs.08244FP","volume":"108","author":"M Hojo","year":"2008","unstructured":"Hojo M, Sudo Y, Ando Y, Minami K, Takada M, Matsubara T, et al. mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharm Sci. 2008;108:308\u201319.","journal-title":"J Pharm Sci"},{"key":"2245_CR26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.bjp.0706757","volume":"148","author":"C Rios","year":"2006","unstructured":"Rios C, Gomes I, Devi LA. mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol. 2006;148:387\u201395.","journal-title":"Br J Pharmacol"},{"key":"2245_CR27","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1097\/00001756-200112040-00017","volume":"12","author":"C Salio","year":"2001","unstructured":"Salio C, Fischer J, Franzoni MF, Mackie K, Kaneko T, Conrath M. CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport. 2001;12:3689\u201392.","journal-title":"Neuroreport"},{"key":"2245_CR28","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1523\/JNEUROSCI.21-03-00823.2001","volume":"21","author":"JJ Rodriguez","year":"2001","unstructured":"Rodriguez JJ, Mackie K, Pickel VM. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci. 2001;21:823\u201333.","journal-title":"J Neurosci"},{"key":"2245_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.neuroscience.2004.05.015","volume":"127","author":"VM Pickel","year":"2004","unstructured":"Pickel VM, Chan J, Kash TL, Rodriguez JJ, MacKie K. Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. Neuroscience. 2004;127:101\u201312.","journal-title":"Neuroscience"},{"key":"2245_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.919773","volume":"15","author":"KC Reeves","year":"2022","unstructured":"Reeves KC, Shah N, Munoz B, Atwood BK. Opioid receptor-mediated regulation of neurotransmission in the brain. Front Mol Neurosci. 2022;15:919773.","journal-title":"Front Mol Neurosci"},{"key":"2245_CR31","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1152\/jn.00603.2006","volume":"97","author":"EL Hill","year":"2007","unstructured":"Hill EL, Gallopin T, Ferezou I, Cauli B, Rossier J, Schweitzer P, et al. Functional CB1 receptors are broadly expressed in neocortical GABAergic and glutamatergic neurons. J Neurophysiol. 2007;97:2580\u20139.","journal-title":"J Neurophysiol"},{"key":"2245_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12399-z","volume":"7","author":"X Han","year":"2017","unstructured":"Han X, He Y, Bi GH, Zhang HY, Song R, Liu QR, et al. CB1 receptor activation on VgluT2-expressing glutamatergic neurons underlies Delta(9)-Tetrahydrocannabinol (Delta(9)-THC)-induced aversive effects in mice. Sci Rep. 2017;7:12315.","journal-title":"Sci Rep"},{"key":"2245_CR33","doi-asserted-by":"publisher","first-page":"8853","DOI":"10.1523\/JNEUROSCI.0988-20.2020","volume":"40","author":"E Galaj","year":"2020","unstructured":"Galaj E, Han X, Shen H, Jordan CJ, He Y, Humburg B, et al. Dissecting the role of GABA neurons in the VTA versus SNr in opioid reward. J Neurosci. 2020;40:8853\u201369.","journal-title":"J Neurosci"},{"key":"2245_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.55782\/ane-2007-1649","volume":"67","author":"M Liguz-Lecznar","year":"2007","unstructured":"Liguz-Lecznar M, Skangiel-Kramska J. Vesicular glutamate transporters (VGLUTs): the three musketeers of glutamatergic system. Acta Neurobiol Exp. 2007;67:207\u201318.","journal-title":"Acta Neurobiol Exp"},{"key":"2245_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0896-6273(01)00344-0","volume":"31","author":"RT Fremeau Jr.","year":"2001","unstructured":"Fremeau RT Jr., Troyer MD, Pahner I, Nygaard GO, Tran CH, Reimer RJ, et al. The expression of vesicular glutamate transporters defines two classes of excitatory synapse. Neuron. 2001;31:247\u201360.","journal-title":"Neuron"},{"key":"2245_CR36","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.tips.2021.03.003","volume":"42","author":"M Favier","year":"2021","unstructured":"Favier M, Pietrancosta N, El Mestikawy S, Gangarossa G. Leveraging VGLUT3 functions to untangle brain dysfunctions. Trends Pharmacol Sci. 2021;42:475\u201390.","journal-title":"Trends Pharmacol Sci"},{"key":"2245_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.phrs.2019.02.014","volume":"142","author":"K Zhou","year":"2019","unstructured":"Zhou K, Zhu Y. The paraventricular thalamic nucleus: a key hub of neural circuits underlying drug addiction. Pharm Res. 2019;142:70\u201376.","journal-title":"Pharm Res"},{"key":"2245_CR38","doi-asserted-by":"crossref","unstructured":"Taylor NE, Pei J, Zhang J, Vlasov KY, Davis T, Taylor E, et al. The role of glutamatergic and dopaminergic neurons in the periaqueductal gray\/dorsal raphe: separating analgesia and anxiety. eNeuro. 2019;6:ENEURO.0018-18.2019.","DOI":"10.1523\/ENEURO.0018-18.2019"},{"key":"2245_CR39","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/ejn.16272","volume":"59","author":"G Poggi","year":"2024","unstructured":"Poggi G, Bergamini G, Dulinskas R, Madur L, Greter A, Ineichen C, et al. Engagement of basal amygdala-nucleus accumbens glutamate neurons in the processing of rewarding or aversive social stimuli. Eur J Neurosci. 2024;59:996\u20131015.","journal-title":"Eur J Neurosci"},{"key":"2245_CR40","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1038\/s41380-023-02182-0","volume":"28","author":"B Hempel","year":"2023","unstructured":"Hempel B, Crissman M, Pari S, Klein B, Bi GH, Alton H, et al. PPARalpha and PPARgamma are expressed in midbrain dopamine neurons and modulate dopamine- and cannabinoid-mediated behavior in mice. Mol Psychiatry. 2023;28:4203\u201314.","journal-title":"Mol Psychiatry"},{"key":"2245_CR41","doi-asserted-by":"publisher","unstructured":"Richner M, Jager SB, Siupka P, Vaegter CB. Hydraulic extrusion of the spinal cord and isolation of dorsal root ganglia in rodents. J Vis Exp. 2017:55226. https:\/\/doi.org\/10.3791\/55226.","DOI":"10.3791\/55226"},{"key":"2245_CR42","doi-asserted-by":"publisher","first-page":"7634","DOI":"10.1021\/acs.jmedchem.6b00860","volume":"59","author":"V Kumar","year":"2016","unstructured":"Kumar V, Bonifazi A, Ellenberger MP, Keck TM, Pommier E, Rais R, et al. Highly selective dopamine D3 receptor (D3R) antagonists and partial agonists based on eticlopride and the D3R crystal structure: new leads for opioid dependence treatment. J Med Chem. 2016;59:7634\u201350.","journal-title":"J Med Chem"},{"key":"2245_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2024.109947","volume":"252","author":"E Galaj","year":"2024","unstructured":"Galaj E, Bi GH, Xi ZX. beta-caryophyllene inhibits heroin self-administration, but does not alter opioid-induced antinociception in rodents. Neuropharmacology. 2024;252:109947.","journal-title":"Neuropharmacology"},{"key":"2245_CR44","doi-asserted-by":"publisher","first-page":"6651","DOI":"10.3390\/ijms25126651","volume":"25","author":"J Socha","year":"2024","unstructured":"Socha J, Grochecki P, Marszalek-Grabska M, Skrok A, Smaga I, Slowik T, et al. Cannabidiol protects against the reinstatement of oxycodone-induced conditioned place preference in adolescent male but not female rats: the role of MOR and CB1R. Int J Mol Sci. 2024;25:6651.","journal-title":"Int J Mol Sci"},{"key":"2245_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12399-z","volume":"7","author":"X Han","year":"2017","unstructured":"Han X, He Y, Bi G-H, Zhang H-Y, Song R, Liu Q-R, et al. CB1 receptor activation on VgluT2-expressing glutamatergic neurons underlies \u03949-tetrahydrocannabinol (\u03949-THC)-induced aversive effects in mice. Sci Rep. 2017;7:12315.","journal-title":"Sci Rep"},{"key":"2245_CR46","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1523\/JNEUROSCI.1493-22.2022","volume":"43","author":"Han","year":"2023","unstructured":"Han, Liang X, Hempel b Y, Jordan CJ, Shen H, Bi G-H, et al. Cannabinoid CB1 receptors are expressed in a subset of dopamine neurons and underlie cannabinoid-induced aversion, hypoactivity, and anxiolytic effects in mice. J Neurosci. 2023;43:373\u201385.","journal-title":"J Neurosci"},{"key":"2245_CR47","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.euroneuro.2020.11.019","volume":"43","author":"X Li","year":"2021","unstructured":"Li X, Hempel BJ, Yang HJ, Han X, Bi GH, Gardner EL, et al. Dissecting the role of CB(1) and CB(2) receptors in cannabinoid reward versus aversion using transgenic CB(1)- and CB(2)-knockout mice. Eur Neuropsychopharmacol. 2021;43:38\u201351.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2245_CR48","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.neuroscience.2005.11.061","volume":"138","author":"HR Weng","year":"2006","unstructured":"Weng HR, Chen JH, Cata JP. Inhibition of glutamate uptake in the spinal cord induces hyperalgesia and increased responses of spinal dorsal horn neurons to peripheral afferent stimulation. Neuroscience. 2006;138:1351\u201360.","journal-title":"Neuroscience"},{"key":"2245_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108131","volume":"173","author":"EE Bagley","year":"2020","unstructured":"Bagley EE, Ingram SL. Endogenous opioid peptides in the descending pain modulatory circuit. Neuropharmacology. 2020;173:108131.","journal-title":"Neuropharmacology"},{"key":"2245_CR50","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.neuroscience.2012.03.038","volume":"213","author":"AR Wilson-Poe","year":"2012","unstructured":"Wilson-Poe AR, Morgan MM, Aicher SA, Hegarty DM. Distribution of CB1 cannabinoid receptors and their relationship with mu-opioid receptors in the rat periaqueductal gray. Neuroscience. 2012;213:191\u2013200.","journal-title":"Neuroscience"},{"key":"2245_CR51","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/bs.apha.2021.10.006","volume":"93","author":"B Hempel","year":"2022","unstructured":"Hempel B, Xi ZX. Receptor mechanisms underlying the CNS effects of cannabinoids: CB(1) receptor and beyond. Adv Pharmacol. 2022;93:275\u2013333.","journal-title":"Adv Pharmacol"},{"key":"2245_CR52","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.lfs.2003.09.038","volume":"74","author":"DL Cichewicz","year":"2004","unstructured":"Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci. 2004;74:1317\u201324.","journal-title":"Life Sci"},{"key":"2245_CR53","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1124\/jpet.102.045575","volume":"304","author":"DL Cichewicz","year":"2003","unstructured":"Cichewicz DL, McCarthy EA. Antinociceptive synergy between delta9-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther. 2003;304:1010\u201315.","journal-title":"J Pharmacol Exp Ther"},{"key":"2245_CR54","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1124\/jpet.113.204099","volume":"345","author":"DR Maguire","year":"2013","unstructured":"Maguire DR, Yang W, France CP. Interactions between mu-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration. J Pharmacol Exp Ther. 2013;345:354\u201362.","journal-title":"J Pharmacol Exp Ther"},{"key":"2245_CR55","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/09540260902782794","volume":"21","author":"SP Welch","year":"2009","unstructured":"Welch SP. Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int Rev Psychiatry. 2009;21:143\u201351.","journal-title":"Int Rev Psychiatry"},{"key":"2245_CR56","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0006-8993(99)01908-3","volume":"848","author":"SP Welch","year":"1999","unstructured":"Welch SP, Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res. 1999;848:183\u201390.","journal-title":"Brain Res"},{"key":"2245_CR57","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.euroneuro.2020.03.002","volume":"36","author":"S Babalonis","year":"2020","unstructured":"Babalonis S, Walsh SL. Therapeutic potential of opioid\/cannabinoid combinations in humans: review of the evidence. Eur Neuropsychopharmacol. 2020;36:206\u201316.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2245_CR58","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1124\/jpet.112.193474","volume":"342","author":"RJ Tallarida","year":"2012","unstructured":"Tallarida RJ. Revisiting the isobole and related quantitative methods for assessing drug synergism. J Pharmacol Exp Ther. 2012;342:2\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"2245_CR59","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1177\/1947601912440575","volume":"2","author":"RJ Tallarida","year":"2011","unstructured":"Tallarida RJ. Quantitative methods for assessing drug synergism. Genes Cancer. 2011;2:1003\u20138.","journal-title":"Genes Cancer"},{"key":"2245_CR60","first-page":"43","volume":"1","author":"J Ma","year":"2019","unstructured":"Ma J, Motsinger-Reif A. Current methods for quantifying drug synergism. Proteom Bioinform. 2019;1:43\u201348.","journal-title":"Proteom Bioinform"},{"key":"2245_CR61","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1124\/jpet.102.045575","volume":"304","author":"DL Cichewicz","year":"2003","unstructured":"Cichewicz DL, McCarthy EA. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther. 2003;304:1010\u20135.","journal-title":"J Pharmacol Exp Ther"},{"key":"2245_CR62","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/sj.bjp.0706045","volume":"144","author":"SM Tham","year":"2005","unstructured":"Tham SM, Angus JA, Tudor EM, Wright CE. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice. Br J Pharmacol. 2005;144:875\u201384.","journal-title":"Br J Pharmacol"},{"key":"2245_CR63","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.brainresbull.2016.07.009","volume":"125","author":"QS Auh","year":"2016","unstructured":"Auh QS, Chun YH, Melemedjian OK, Zhang Y, Ro JY. Peripheral interactions between cannabinoid and opioid receptor agonists in a model of inflammatory mechanical hyperalgesia. Brain Res Bull. 2016;125:211\u20137.","journal-title":"Brain Res Bull"},{"key":"2245_CR64","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/sj.npp.1301127","volume":"32","author":"M Ellgren","year":"2007","unstructured":"Ellgren M, Spano SM, Hurd YL. Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology. 2007;32:607\u201315.","journal-title":"Neuropsychopharmacology"},{"key":"2245_CR65","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0014-2999(03)01455-9","volume":"465","author":"CS Norwood","year":"2003","unstructured":"Norwood CS, Cornish JL, Mallet PE, McGregor IS. Pre-exposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats. Eur J Pharmacol. 2003;465:105\u201314.","journal-title":"Eur J Pharmacol"},{"key":"2245_CR66","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/sj.npp.1300431","volume":"29","author":"M Solinas","year":"2004","unstructured":"Solinas M, Panlilio LV, Goldberg SR. Exposure to delta-9-tetrahydrocannabinol (THC) increases subsequent heroin taking but not heroin\u2019s reinforcing efficacy: a self-administration study in rats. Neuropsychopharmacology. 2004;29:1301\u201311.","journal-title":"Neuropsychopharmacology"},{"key":"2245_CR67","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.biopsych.2012.04.026","volume":"72","author":"HC Tomasiewicz","year":"2012","unstructured":"Tomasiewicz HC, Jacobs MM, Wilkinson MB, Wilson SP, Nestler EJ, Hurd YL. Proenkephalin mediates the enduring effects of adolescent cannabis exposure associated with adult opiate vulnerability. Biol Psychiatry. 2012;72:803\u201310.","journal-title":"Biol Psychiatry"},{"key":"2245_CR68","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0006-8993(98)00766-5","volume":"807","author":"G Vela","year":"1998","unstructured":"Vela G, Martin S, Garcia-Gil L, Crespo JA, Ruiz-Gayo M, Fernandez-Ruiz JJ, et al. Maternal exposure to delta9-tetrahydrocannabinol facilitates morphine self-administration behavior and changes regional binding to central mu opioid receptors in adult offspring female rats. Brain Res. 1998;807:101\u20139.","journal-title":"Brain Res"},{"key":"2245_CR69","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1111\/j.1460-9568.2003.02961.x","volume":"18","author":"S Caille","year":"2003","unstructured":"Caille S, Parsons LH. SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats. Eur J Neurosci. 2003;18:3145\u20139.","journal-title":"Eur J Neurosci"},{"key":"2245_CR70","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/sj.npp.1300848","volume":"31","author":"S Caille","year":"2006","unstructured":"Caille S, Parsons LH. Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway. Neuropsychopharmacology. 2006;31:804\u201313.","journal-title":"Neuropsychopharmacology"},{"key":"2245_CR71","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41401-018-0059-x","volume":"40","author":"XH He","year":"2019","unstructured":"He XH, Jordan CJ, Vemuri K, Bi GH, Zhan J, Gardner EL, et al. Cannabinoid CB(1) receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats. Acta Pharmacol Sin. 2019;40:365\u201373.","journal-title":"Acta Pharmacol Sin"},{"key":"2245_CR72","doi-asserted-by":"publisher","first-page":"5344","DOI":"10.1523\/JNEUROSCI.21-14-05344.2001","volume":"21","author":"M Navarro","year":"2001","unstructured":"Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci. 2001;21:5344\u201350.","journal-title":"J Neurosci"},{"key":"2245_CR73","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1097\/01.wnr.0000126217.87116.8c","volume":"15","author":"C Manzanedo","year":"2004","unstructured":"Manzanedo C, Aguilar MA, Rodriguez-Arias M, Navarro M, Minarro J. Cannabinoid agonist-induced sensitisation to morphine place preference in mice. Neuroreport. 2004;15:1373\u20137.","journal-title":"Neuroreport"},{"key":"2245_CR74","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bbr.2013.03.022","volume":"247","author":"S Karimi","year":"2013","unstructured":"Karimi S, Azizi P, Shamsizadeh A, Haghparast A. Role of intra-accumbal cannabinoid CB1 receptors in the potentiation, acquisition and expression of morphine-induced conditioned place preference. Behav Brain Res. 2013;247:125\u201331.","journal-title":"Behav Brain Res"},{"key":"2245_CR75","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1038\/sj.bjp.0703990","volume":"132","author":"M Mas-Nieto","year":"2001","unstructured":"Mas-Nieto M, Pommier B, Tzavara ET, Caneparo A, Da Nascimento S, Le Fur G, et al. Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol. 2001;132:1809\u201316.","journal-title":"Br J Pharmacol"},{"key":"2245_CR76","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.bbr.2013.03.015","volume":"247","author":"A Rashidy-Pour","year":"2013","unstructured":"Rashidy-Pour A, Pahlevani P, Vaziri A, Shaigani P, Zarepour L, Vafaei AA, et al. Involvement of CB1 receptors in the ventral tegmental area in the potentiation of morphine rewarding properties in acquisition but not expression in the conditioned place preference model. Behav Brain Res. 2013;247:259\u201367.","journal-title":"Behav Brain Res"},{"key":"2245_CR77","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neulet.2016.07.047","volume":"630","author":"J Zhang","year":"2016","unstructured":"Zhang J, Wang N, Chen B, Wang Y, He J, Cai X, et al. Blockade of cannabinoid CB1 receptor attenuates the acquisition of morphine-induced conditioned place preference along with a downregulation of ERK, CREB phosphorylation, and BDNF expression in the nucleus accumbens and hippocampus. Neurosci Lett. 2016;630:70\u201376.","journal-title":"Neurosci Lett"},{"key":"2245_CR78","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1016\/S0014-2999(99)00656-1","volume":"383","author":"MS Mascia","year":"1999","unstructured":"Mascia MS, Obinu MC, Ledent C, Parmentier M, Bohme GA, Imperato A, et al. Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mice. Eur J Pharmacol. 1999;383:R1\u20132.","journal-title":"Eur J Pharmacol"},{"key":"2245_CR79","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.neuropharm.2019.04.010","volume":"151","author":"JD Nguyen","year":"2019","unstructured":"Nguyen JD, Grant Y, Creehan KM, Hwang CS, Vandewater SA, Janda KD, et al. Delta(9)-tetrahydrocannabinol attenuates oxycodone self-administration under extended access conditions. Neuropharmacology. 2019;151:127\u201335.","journal-title":"Neuropharmacology"},{"key":"2245_CR80","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0091-3057(03)00115-1","volume":"75","author":"B Gonzalez","year":"2003","unstructured":"Gonzalez B, de Miguel R, Martin S, Perez-Rosado A, Romero J, Garcia-Lecumberri C, et al. Effects of perinatal exposure to delta 9-tetrahydrocannabinol on operant morphine-reinforced behavior. Pharmacol Biochem Behav. 2003;75:577\u201384.","journal-title":"Pharmacol Biochem Behav"},{"key":"2245_CR81","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.brainres.2004.08.027","volume":"1026","author":"ME Singh","year":"2004","unstructured":"Singh ME, Verty AN, McGregor IS, Mallet PE. A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine. Brain Res. 2004;1026:244\u201353.","journal-title":"Brain Res"},{"key":"2245_CR82","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1111\/adb.12406","volume":"22","author":"T Ahmad","year":"2017","unstructured":"Ahmad T, Sun N, Lyons D, Laviolette SR. Bi-directional cannabinoid signalling in the basolateral amygdala controls rewarding and aversive emotional processing via functional regulation of the nucleus accumbens. Addict Biol. 2017;22:1218\u201331.","journal-title":"Addict Biol"},{"key":"2245_CR83","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1023\/A:1007058008477","volume":"20","author":"M Shapira","year":"2000","unstructured":"Shapira M, Vogel Z, Sarne Y. Opioid and cannabinoid receptors share a common pool of GTP-binding proteins in cotransfected cells, but not in cells which endogenously coexpress the receptors. Cell Mol Neurobiol. 2000;20:291\u2013304.","journal-title":"Cell Mol Neurobiol"},{"key":"2245_CR84","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S0022-5347(25)00276-9","volume":"241","author":"PJ Vaysse","year":"1987","unstructured":"Vaysse PJ, Gardner EL, Zukin RS. Modulation of rat brain opioid receptors by cannabinoids. J Pharmacol Exp Ther. 1987;241:534\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"2245_CR85","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S1569-9048(03)00173-3","volume":"138","author":"T Lonergan","year":"2003","unstructured":"Lonergan T, Goodchild AK, Christie MJ, Pilowsky PM. Mu opioid receptors in rat ventral medulla: effects of endomorphin-1 on phrenic nerve activity. Respir Physiol Neurobiol. 2003;138:165\u201378.","journal-title":"Respir Physiol Neurobiol"},{"key":"2245_CR86","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/cne.903270406","volume":"327","author":"LA Matsuda","year":"1993","unstructured":"Matsuda LA, Bonner TI, Lolait SJ. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol. 1993;327:535\u201350.","journal-title":"J Comp Neurol"},{"key":"2245_CR87","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991","volume":"11","author":"M Herkenham","year":"1991","unstructured":"Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991;11:563\u201383.","journal-title":"J Neurosci"},{"key":"2245_CR88","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nature16954","volume":"530","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Wienecke CF, Nachtrab G, Chen X. A thalamic input to the nucleus accumbens mediates opiate dependence. Nature. 2016;530:219\u201322.","journal-title":"Nature"},{"key":"2245_CR89","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1046\/j.0953-816x.2001.01558.x","volume":"13","author":"O Valverde","year":"2001","unstructured":"Valverde O, Noble F, Beslot F, Dauge V, Fournie-Zaluski MC, Roques BP. Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci. 2001;13:1816\u201324.","journal-title":"Eur J Neurosci"},{"key":"2245_CR90","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0014-2999(97)00144-1","volume":"323","author":"J Corchero","year":"1997","unstructured":"Corchero J, Fuentes JA, Manzanares J. delta 9-Tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus. Eur J Pharmacol. 1997;323:193\u20135.","journal-title":"Eur J Pharmacol"},{"key":"2245_CR91","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/sj.npp.1300117","volume":"28","author":"D Vigano","year":"2003","unstructured":"Vigano D, Grazia Cascio M, Rubino T, Fezza F, Vaccani A, Di Marzo V, et al. Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain. Neuropsychopharmacology. 2003;28:1160\u20137.","journal-title":"Neuropsychopharmacology"},{"key":"2245_CR92","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1111\/j.1460-9568.2004.03645.x","volume":"20","author":"D Vigano","year":"2004","unstructured":"Vigano D, Valenti M, Cascio MG, Di Marzo V, Parolaro D, Rubino T. Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine. Eur J Neurosci. 2004;20:1849\u201357.","journal-title":"Eur J Neurosci"},{"key":"2245_CR93","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1523\/JNEUROSCI.4403-06.2007","volume":"27","author":"S Caille","year":"2007","unstructured":"Caille S, Alvarez-Jaimes L, Polis I, Stouffer DG, Parsons LH. Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci. 2007;27:3695\u2013702.","journal-title":"J Neurosci"},{"key":"2245_CR94","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0376-8716(98)00036-2","volume":"50","author":"J Romero","year":"1998","unstructured":"Romero J, Fernandez-Ruiz JJ, Vela G, Ruiz-Gayo M, Fuentes JA, Ramos JA. Autoradiographic analysis of cannabinoid receptor binding and cannabinoid agonist-stimulated [35S]GTP gamma S binding in morphine-dependent mice. Drug Alcohol Depend. 1998;50:241\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"2245_CR95","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0014-2999(94)90003-5","volume":"260","author":"SN Thorat","year":"1994","unstructured":"Thorat SN, Bhargava HN. Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice. Eur J Pharmacol. 1994;260:5\u201313.","journal-title":"Eur J Pharmacol"},{"key":"2245_CR96","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/npp.2015.351","volume":"41","author":"E Martin-Garcia","year":"2016","unstructured":"Martin-Garcia E, Bourgoin L, Cathala A, Kasanetz F, Mondesir M, Gutierrez-Rodriguez A, et al. Differential control of cocaine self-administration by GABAergic and glutamatergic CB1 cannabinoid receptors. Neuropsychopharmacology. 2016;41:2192\u2013205.","journal-title":"Neuropsychopharmacology"},{"key":"2245_CR97","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3389\/fnins.2019.00484","volume":"13","author":"H Zhu","year":"2019","unstructured":"Zhu H, Xiang HC, Li HP, Lin LX, Hu XF, Zhang H, et al. Inhibition of GABAergic neurons and excitation of glutamatergic neurons in the ventrolateral periaqueductal gray participate in electroacupuncture analgesia mediated by cannabinoid receptor. Front Neurosci. 2019;13:484.","journal-title":"Front Neurosci"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02245-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02245-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02245-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T23:02:34Z","timestamp":1765926154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02245-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2245"],"URL":"https:\/\/doi.org\/10.1038\/s41386-025-02245-6","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"20 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}